

CURRICULUM VITAE

Dr. Zhang received his Ph.D degree in Genetics from Chinese Academy of Sciences, Beijing, in 2003. Afterwards, he moved to Cologne, Germany and got his postdoctoral training in University of Cologne. He is currently a professor in Shanghai Cancer Institute, Shanghai Jiao Tong University. His major research interests are the secreted factors in tumor microenvironment including neurotransmitters, hormones, extracellular matrix (ECM), stromal cells, cytokines, etc. He has published more than 40 peer-reviewed paper in international journals, e.g. *Hepatology*, *Journal of Hepatology*, *Oncogene*, *Oncotarget*, etc. As a principal investigator, he has been granted by National Key Sci-Tech Special Projects of Infectious Diseases, National High-tech R&D Program of China (863 project), the National Science Foundation of China, etc.

Selected Publications

1. Nie H, Li J, Yang XM, Cao QZ, Feng MX, Xue F, Wei L, Qin W, Gu J, Xia Q, **Zhang ZG***. Mineralocorticoid receptor suppresses cancer progression and Warburg effect by modulating miR-338-3p-PKLR axis in hepatocellular carcinoma. *Hepatology*. 2015 Oct;62(4):1145-59. doi: 10.1002/hep.27940. [Epub ahead of print] (***Corresponding author**)
2. Li J, Yang XM, Wang YH, Feng MX, Liu XJ, Zhang YL, Huang S, Wu Z, Xue F, Qin WX, Gu JR, Xia Q, **Zhang ZG***. Monoamine oxidase A suppresses Hepatocellular Carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. *Journal of Hepatology*, 2014 Jun;60(6):1225-34. doi: 10.1016/j.jhep.2014.02.025. Epub 2014 Mar 6. (***Corresponding author**)
3. Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, Sun WW, Lou XL, Wang JH, Teng YC, **Zhang ZG***. miR-506 acts as a tumor suppressor by directly targeting the Hedgehog pathway transcription factor

Gli3 in human cervical cancer. *Oncogene*, 2015 Feb 5;34(6):717-25.
(*Corresponding author)

4. Zhu LY, Zhang WM, Yang XM, Cui L, Li J, Zhang YL, Wang YH, Ao JP, Ma MZ, Lu H, Ren Y, Xu SH, Yang GD, Song WW, Wang JH, Zhang XD, Zhang R, **Zhang ZG***. Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition. *Cancer Lett.* 2015 Jul 10;363(1):71-82. (*Corresponding author)
5. Yang JY, Jiang SH, Liu DJ, Yang XM, Huo YM, Li J, Hua R, **Zhang ZG**, Sun YW. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. *Sci Rep.* 2015 May 27;5:10575. (*Corresponding author)
6. Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H, Zhang WM, You HY, Qin W, Gu J, Yang S, Cao H, **Zhang ZG***. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. *Neoplasia*, 2014 Mar;16(3):265-78, 278.e1-13 (*Corresponding author)
7. Fu Y, Feng MX, Yu J, Ma MZ, Liu XJ, Li J, Yang XM, Wang YH, Zhang YL, Ao JP, Xue F, Qin W, Gu J, Xia Q and **Zhang ZG***. DNA methylation-mediated silencing of matricellular protein dermatopontin promotes hepatocellular carcinoma metastasis by $\alpha 3\beta 1$ integrin-Rho GTPase signaling. *Oncotarget*, 2014 Aug 30;5(16):6701-15 (*Corresponding author)
8. Feng MX, Ma MZ, Fu Y, Li J, Wang T, Xue F, Zhang JJ, Qin WX, Gu JR, Zhang ZG, Xia Q. Elevated autocrine EDIL3 protects hepatocellular carcinoma from anoikis through RGD-mediated integrin activation. *Mol Cancer.* 2014 Oct 1;13:226. (*Corresponding author)
9. Liu XJ, Xu MJ, Fan ST, Wu Z, Li J, Yang XM, Wang YH, Xu J and **Zhang ZG***. Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress. *J Invest Dermatol.* 2013 May;133(5):1351-60. doi: 10.1038/jid.2012.486. Epub 2013 Jan 10. (*Corresponding author)
10. Liu XJ, Kong FZ, Wang YH, Zheng JH, Wan WD, Deng CL, Mao GY, Li J, Yang

- XM, Zhang YL, Zhang XL, Yang SL, **Zhang ZG***. Lumican Accelerates Wound Healing by Enhancing $\alpha 2\beta 1$ Integrin-Mediated Fibroblast Contractility. *PLoS One*. 2013 Jun 26;8(6):e67124. Print 2013. (*Corresponding author)
11. Lin L, Yang XM, Li J, Zhang YL, Qin W, **Zhang ZG***. Microfilament regulatory protein MENA increases activity of RhoA and promotes metastasis of hepatocellular carcinoma. *Exp Cell Res*. 2014 Sep 10;327(1):113-22. (*Corresponding author)
12. Xu MJ, Liu XJ, Zhao YL, Liu D, Xu ZH, Lang XM, Ao P, Lin WH, Yang SL, **Zhang ZG***, Xu J. Identification and Characterization of an Anti-Fibrotic Benzopyran Compound Isolated from Mangrove-Derived *Streptomyces xiamenensis*. *Mar Drugs*. 2012 March; 10(3): 639 – 654. (*Co-corresponding author)
13. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, **Zhang Z**, Yang S, Gu J, Wang H, Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. *Lancet Oncol*. 2012 Aug;13(8):817-26.
14. Fan S, Niu Y, Tan N, Wu Z, Wang Y, You H, Ke R, Song J, Shen Q, Wang W, Yao G, Shu H, Lin H, Yao M, **Zhang Z**, Gu J, Qin W. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. *Oncogene*. 2013 Mar 28;32(13):1682-90. doi: 10.1038/onc.2012.183. Epub 2012 May 14.